✦ LIBER ✦

A Phase I safety and immunogenicity trial of UBI® microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects

✍ Scribed by John S Lambert; Michael Keefer; Mark J Mulligan; David Schwartz; Jiri Mestecky; Kent Weinhold; Carol Smith; Ray Hsieh; Zina Moldoveanu; Patricia Fast; Bruce Forrest; Wayne Koff

Book ID: 117430350
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 151 KB
Volume: 19
Category: Article
ISSN: 0264-410X
DOI: 10.1016/s0264-410x(01)00051-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and immunogenicity of a randomize

Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene

✍ RJ O’Connell, VR Polonis, S Ratto-Kim, J Cox, LL Jagodzinski, J Malia… 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 68 KB

Lessons from IAVI-006, a Phase I clinica

Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers

✍ A. Guimarães-Walker; N. Mackie; S. McCormack; T. Hanke; C. Schmidt; J. Gilmour; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 498 KB

Corrigendum to “Lessons from IAVI-006, a

Corrigendum to “Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers” [Vaccine 26 (2008) 6671–6677]

✍ A. Guimarães-Walker; N. Mackie; S. McCormack; T. Hanke; C. Schmidt; J. Gilmour; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 91 KB